71% of patients were considered responders at 4 weeks follow up. This was maintained in 91% and 94% at 3 and 6 months follow up. There was a reduction of 6 voids and 6 incontinence episodes per day at 6 months follow up. Quality of life scores improved during this time as well. 83% of patients reported that they were moderately or very satisfied with their therapy. The authors report that there were no serious device related adverse events.
The authors reported an improvement in symptoms and patient satisfaction with this new rechargeable SNM system for refractory OAB, which they hope will lead to a decrease in frequency of revisions needed.
Presented by: Stefan De Wachter, MD, PhD1
Co-Authors: Bertil Blok ², Philip Van Kerrebroeck ³, Alain Rufion ⁴, Frank Van der Aa ⁵, Marie Aimee Perrouin Verbe ⁶, Ranjana Jairam ³ and Suzy Elneil ⁷
1. Dept Urology, University hospital antwerpen, university Antwerpen, belgium
2. Erasmus MC, Rotterdam, The Netherlands
3. Maastricht University Medical Centre, Maastricht, The Netherlands
4. Hôpital Lyon Sud, Pierre Bénite, Lyon, France
5. UZ Leuven, Leuven, Belgium; ⁶University Hospital of Nantes, Nantes, France; ⁷National Hospital of Neurology and Neurosurgery, London, United Kingdom
Written by: Cristina Palmer, DO. Female Urology, Pelvic Reconstruction, Voiding Dysfunction Fellow, Department of Urology, UC Irvine Medical Center, Orange, California at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting (SUFU 2018), February 27-March 3, 2018, Austin, Texas